Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism.
Company profile
Ticker
INDP, NTEC
Exchange
Website
CEO
Jeffrey Meckler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Intec Pharma Inc. • Intec Parent, Inc. • Dillon Merger Sub, Inc. • Domestication Merger Sub Ltd. ...
INDP stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
13 Aug 21
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Aug 21
25-NSE
Exchange delisting
3 Aug 21
425
Business combination disclosure
29 Jul 21
8-K
Intec Announces $30 Million Private Placement Ahead of Decoy Merger
29 Jul 21
425
Business combination disclosure
23 Jul 21
8-K
Other Events
23 Jul 21
425
Business combination disclosure
16 Jul 21
8-K
Other Events
16 Jul 21
425
Business combination disclosure
22 Jun 21
Latest ownership filings
SC 13G/A
CVI Investments, Inc.
16 Feb 21
SC 13G/A
INTRACOASTAL CAPITAL, LLC
29 Jan 21
SC 13G/A
SABBY MANAGEMENT, LLC
4 Jan 21
SC 13G/A
MEITAV DASH INVESTMENTS LTD
4 Nov 20
4
Nir Sassi
18 Sep 20
4
Walt Addison Linscott
18 Sep 20
4
Nadav Navon
18 Sep 20
4
Roger Pomerantz
17 Jul 20
4
Jeffrey A Meckler
17 Jul 20
4
ANTHONY J MADDALUNA
17 Jul 20
Financial summary
Quarter (USD) | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.14 mm | 11.14 mm | 11.14 mm | 11.14 mm | 11.14 mm | 11.14 mm |
Cash burn (monthly) | 1.18 mm | (no burn) | 1.40 mm | 1.20 mm | 1.44 mm | 889.58 k |
Cash used (since last report) | 43.18 mm | n/a | 51.40 mm | 43.99 mm | 52.64 mm | 32.59 mm |
Cash remaining | -32.05 mm | n/a | -40.26 mm | -32.85 mm | -41.51 mm | -21.46 mm |
Runway (months of cash) | -27.2 | n/a | -28.7 | -27.4 | -28.9 | -24.1 |
Institutional ownership, Q3 2021
4.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 11 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 1.25 mm |
Total shares | 360.93 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 265.93 k | $917.00 k |
CVI Investments | 95.00 k | $328.00 k |